Krishnan Nandabalan, Director, 10% Owner at BioXcel Therapeutics, Inc. (BTAI), bought 1,000 shares at $4.92 ($5K) on 2018-11-29, disclosed to the SEC on 2018-11-30.
Open-market purchase of $5k BTAI by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| Filing → |
| BTAI | SELL | 2022-11-14 | $900K | — | Filing → |
| BTAI | SELL | 2021-06-29 | $29.2M | — | Filing → |